SPRAVATO® vs Ketamine: Which Rapid-Acting Antidepressant Is Right for You?

Spravato® vs Ketamine: Which Rapid-Acting Antidepressant Is Right for You?

Table of Contents

1. Quick Comparison: Spravato® vs Ketamine
2. FDA Approval & Legal Status
3. Route of Administration
4. REMS vs No REMS
5. Efficacy & Response Rates
6. Dissociation & Side Effects
7. Cognitive Safety: Long-Term Implications
8. Insurance Coverage & Cost
9. Which Is Right for You?
10. Frequently Asked Questions

Key Takeaways

• Spravato® is FDA-approved (2019), intranasal, REMS-regulated, self-administered in office; Ketamine is off-label, IV, no REMS, clinician-administered
• Efficacy: Spravato® 25–65% response rate; IV ketamine estimated 40–70%, though less robust FDA data
• Dissociation: Spravato® 41% (monitored 2-hour window); IV ketamine more intense but also monitored
• Long-term cognition: Esketamine (Spravato®) maintains/improves cognition; racemic ketamine may impair cognition chronically
• Insurance: Most major insurers cover Spravato®; IV ketamine often out-of-pocket
• Cost: Spravato® ~$179/dose (self-pay); IV ketamine $500–1,000/session (often uninsured)
• Best for Spravato®: TRD with multiple failed trials, acute suicidal ideation, preference for intranasal, good insurance
• Best for Ketamine: Higher efficacy expectations, prefer IV, no REMS restrictions, willing to self-pay, access to experienced ketamine clinic

Quick Comparison: Spravato® vs Ketamine

Both Spravato® (intranasal esketamine) and IV ketamine are rapid-acting antidepressants that work on the glutamatergic system, offering hope for treatment-resistant depression. However, they differ significantly in FDA approval status, administration route, regulatory requirements, cognitive safety, and cost.

Side-by-Side Overview

FDA Approval & Legal Status

Spravato®: FDA-Approved Medication

Spravato® (esketamine) was approved by the FDA on September 20, 2019 for treatment-resistant depression, making it the first and only FDA-approved intranasal rapid-acting antidepressant. It is indicated only for treatment-resistant depression (TRD) and for depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior, and must be administered in a REMS-certified setting with monitoring. This approval came after rigorous Phase 3 randomized controlled trials demonstrating:

• Efficacy for TRD: Significant symptom reduction compared to placebo in patients with failed antidepressant trials
• Efficacy for Suicidal Crisis: Rapid reduction in suicidal ideation/behavior within hours

The FDA approval means:

• Evidence-based: Spravato®'s safety and efficacy are validated through large-scale clinical trials
• Insurance coverage: Most insurance companies recognize FDA-approved status and cover the treatment
• Quality standards: Manufacturing, purity, and dosing are standardized under FDA oversight
• Medical liability: FDA approval provides regulatory protection for prescribers and patients

IV Ketamine: Off-Label Use

IV ketamine is not FDA-approved for depression treatment. Instead, ketamine is:

• FDA-approved for anesthesia only (1970s approval for surgical use)
• Used off-label for depression: Based on clinical experience and growing evidence, but without formal FDA indication
• Variable regulation: Each clinic operates under their own protocols; no standardized REMS program
• Insurance limitations: Off-label status means most insurance companies will not cover IV ketamine, requiring out-of-pocket payment

The off-label use of ketamine for depression is legal and increasingly common, supported by meta-analyses and real-world evidence. However, it lacks the regulatory oversight and insurance coverage of FDA-approved treatments.

Route of Administration

Spravato®: Intranasal Self-Administration

Spravato® is self-administered as a nasal spray in a REMS-certified physician's office:

• Self-delivery: Patient uses a metered-dose applicator to spray medication into each nostril
• Healthcare provider oversight: Clinician directly observes administration and is present throughout 2-hour monitoring
• No IV line required: Non-invasive; eliminates vein access concerns
• Faster administration: 5–10 minutes from arrival to dose completion
• Accessibility: Intranasal route is less intimidating for some patients fearful of IV needles

Advantages: Non-invasive, rapid administration, patient control, reduced anxiety for needle-phobic patients

Disadvantages: Nasal tolerance/irritation with repeated dosing, potential mucociliary clearance variation, possible dosing inconsistency with nasal obstruction

IV Ketamine: Intravenous Administration

IV ketamine is administered through an intravenous line, typically by a nurse or clinician in a specialized ketamine clinic:

• Clinician-administered: Healthcare provider places IV line and infuses medication over 40–60 minutes
• Direct bloodstream access: Ensures complete and consistent medication delivery
• Pharmacokinetic predictability: IV route provides more consistent drug levels
• Higher intensity dissociation: IV administration produces more intense, faster-onset dissociative effects (within 5–15 minutes)

Advantages: Direct drug delivery, pharmacokinetically predictable, potentially faster onset, higher perceived intensity

Disadvantages: Invasive (requires IV line), vein access challenges, higher dissociation burden, longer infusion time (40–60 min vs 5–10 min), greater vascular complications risk

REMS vs No REMS

Spravato®: FDA REMS Program

Spravato® operates under a strict Risk Evaluation and Mitigation Strategy (REMS) program, meaning:

• Certified Pharmacy: Medications distributed only through REMS-certified pharmacies
• Certified Providers: Healthcare providers must be REMS-certified to administer
• Certified Facilities: Administration must occur in REMS-certified office settings
• Patient Training: All patients must complete REMS education before treatment
• Office Administration Only: Spravato® cannot be taken home or self-administered outside a medical facility
• Monitoring Requirement: 2-hour supervised post-administration monitoring is mandatory
• Structured Reporting: All adverse events reported to the REMS database

Why REMS for Spravato®?

• Dissociation and sedation common; unmonitored use could lead to falls, accidents, impaired judgment
• Blood pressure elevation risk; monitoring allows immediate intervention
• Need to ensure safe use of a novel, rapid-acting medication

Impact on Patients: REMS makes Spravato® less convenient (must visit office, cannot take home) but ensures standardized safety protocols and medical oversight.

IV Ketamine: No REMS Program

IV ketamine operates without an FDA REMS program, meaning:

• Provider discretion: Each ketamine clinic develops its own protocols and monitoring standards
• Variable safety standards: Safety procedures vary widely clinic-to-clinic
• Home infusion possible: Some clinics offer home infusions of ketamine (though not standard)
• Minimal regulatory oversight: No federal requirement for certified facilities or providers
• Patient freedom: No government-mandated patient education or agreement required

Potential Advantages: More flexibility in treatment scheduling, potentially more clinics available, less bureaucratic burden

Potential Disadvantages: Less standardized safety monitoring, variable quality between clinics, higher risk of adverse events, inconsistent medical oversight

Efficacy & Response Rates

Spravato® Response Rates

Clinical trials for Spravato® in TRD have shown:

• Overall response rate: 25–65% (varies by trial and definition of "response")
• Remission rate: 20–35% (significant symptom reduction or full remission)
• Onset: Response may occur within 2–4 hours of first dose; full benefit emerges over 4 weeks
• Maintenance: 70–80% of initial responders maintain benefit with continued treatment

Key Trial Data:

• TRANSFORM-1 & TRANSFORM-2 (Phase 3): Spravato® + antidepressant vs. placebo + antidepressant showed statistically significant improvement in TRD patients
• SUSTAIN-1 & SUSTAIN-2 (maintenance): Long-term benefit sustained with continued dosing

IV Ketamine Response Rates

IV ketamine efficacy estimates vary because most data comes from clinical practice rather than FDA-regulated trials:

• Estimated response rate: 40–70% (based on real-world reports and smaller studies)
• Remission rate: 30–50% (varies widely by clinic and patient population)
• Onset: Rapid within 1–2 hours of infusion; some effects within 30 minutes
• Maintenance: Relapse risk higher with ketamine than Spravato®; relapse can occur within days to weeks of stopping treatment

Why the Uncertainty?

• Off-label use means fewer large randomized controlled trials
• Variable patient selection between clinics (some pre-select sicker populations, improving apparent efficacy)
• Different dosing protocols, infusion durations, and follow-up schedules make comparison difficult
• Publication bias: Successful cases may be more likely reported than failures

Clinical Bottom Line: IV ketamine may have slightly higher efficacy than Spravato® based on anecdotal reports, but robust FDA-grade data is lacking. Spravato®'s FDA-approved efficacy range (25–65%) should not be viewed as "lower" than ketamine—rather, it represents validated clinical evidence.

Dissociation & Side Effects

Spravato® Dissociation Profile

Dissociation is the most common adverse effect of Spravato®:

• Incidence: 41% of patients vs. 9% placebo
• Onset: 5–20 minutes post-administration
• Peak: 30–60 minutes
• Duration: Resolves by end of 2-hour monitoring period; nearly complete resolution
• Description: Feeling "floaty," detached from body, altered perception, mild depersonalization
• Severity: Generally mild-to-moderate; severe dissociation rare
• Management: Reassurance, continued monitoring; cognitive dissociation resolves completely

Other Common Spravato® Adverse Effects:

• Dizziness (29%)
• Nausea (28%)
• Sedation (23%)
• Vertigo (23%)
• Hypertension (10%)

Safety Profile: Because Spravato® is administered in a monitored setting for 2 hours, dissociation and other side effects are observed and managed in real-time. By discharge, patients are oriented, cognitively intact, and safe.

IV Ketamine Dissociation Profile

IV ketamine produces dissociation as a direct pharmacologic effect:

• Incidence: Highly variable (60–80%+ depending on dose)
• Onset: Within 5–15 minutes (faster than Spravato® due to IV route)
• Peak: 30–45 minutes; more intense than Spravato®
• Duration: 1–2 hours post-infusion; resolves by end of monitoring
• Severity: Often moderate-to-significant dissociation; some patients report profound out-of-body experiences
• Description: Intense perceptual distortion, feeling "disconnected," dream-like state, loss of bodily awareness
• Subjective experience: For some patients, dissociation is therapeutically valuable (associated with rapid symptom relief); for others, it's distressing and a barrier to continuing treatment

Other Common IV Ketamine Adverse Effects:

• Dizziness and vertigo
• Nausea and vomiting
• Sedation
• Tachycardia (increased heart rate)
• Hypertension
• Anxiety or panic during dissociation (less common with Spravato®)

Clinical Implications: IV ketamine's more intense dissociation is part of its mechanism but can limit tolerability. Some patients find the dissociative experience psychologically valuable (insight, perspective shift); others find it distressing and discontinue treatment.

Cognitive Safety: Long-Term Implications

Spravato®: Cognitive Preservation

A major advantage of Spravato® (esketamine) is its long-term cognitive safety profile:

• Long-term data: Patients on esketamine for 6–12 months show maintained or slightly improved cognitive function (memory, attention, executive function)
• Mechanism: The S-enantiomer of ketamine may be neuroprotective; NMDA blockade + AMPA activation promotes neuroplasticity
• Clinical relevance: Safe for chronic use; no evidence of neurotoxicity with extended treatment
• Reversal on discontinuation: If cognitive changes occurred (rare), they resolve after stopping medication

Clinical Bottom Line: Spravato® is safe for long-term, even indefinite, use from a cognitive perspective.

IV Ketamine: Cognitive Concerns

IV ketamine raises long-term cognitive safety questions, particularly with chronic use:

• Animal models: Chronic ketamine exposure in rodent studies shows evidence of neurotoxicity, neuroinflammation, and hippocampal damage
• Human clinical data: Limited but concerning reports of memory impairment, attention deficits, and cognitive decline with chronic IV ketamine (especially at higher cumulative doses)
• Mechanism concern: Racemic ketamine (1:1 mixture of R and S enantiomers) may have less selective NMDA antagonism than esketamine, potentially leading to off-target effects
• Chronic use: Unknown long-term safety profile; most users limit to acute/continuation phases (3–12 months)

Clinical Bottom Line: IV ketamine's long-term cognitive safety is uncertain. Providers often limit chronic use to 6–12 months, then discontinue or switch to alternative treatments due to unknown long-term risks.

This difference is critical for patients considering extended treatment beyond acute depression resolution.

Insurance Coverage & Cost

Spravato® Insurance Coverage

Most major insurance companies now cover FDA-approved Spravato®:

• Aetna: Covered
• BCBS: Covered
• Cigna: Covered
• UnitedHealthcare: Covered
• Medicare: Covered
• Optum, Oscar, First Health: Covered

Coverage Details:

• Prior authorization typically required
• Copay/coinsurance: $0–150/dose (varies by plan)
• Deductible usually applies first
• Annual out-of-pocket maximum applies

Self-Pay Cost at KwikPsych:

• Initial evaluation: $299
• Treatment dose: $179/dose
• Acute phase (8 doses): ~$1,432 + eval = ~$1,731 total

IV Ketamine Insurance Coverage

Most insurance companies DO NOT cover off-label IV ketamine:

• Reason: Off-label status; no FDA indication; insurers often deny claims
• Result: Patients pay entirely out-of-pocket
• Some exceptions: Medicare, military insurance, or specific state Medicaid plans may occasionally cover, but rare

Self-Pay Cost for IV Ketamine:

• Initial evaluation: $200–500
• Single infusion session: $500–1,500
• Acute phase (6–12 sessions): $3,000–18,000
• Maintenance doses (if chronic): $500–1,500/session

Cost Comparison Over 4-Week Acute Phase:

Insurance Winner: Spravato® (with insurance coverage)

Which Is Right for You?

Choose Spravato® If You:

• Have treatment-resistant depression that has failed 2+ antidepressant trials
• Have acute suicidal ideation (Spravato® is FDA-approved for this indication)
• Have insurance coverage for Spravato® (most major carriers do)
• Prefer intranasal vs. IV administration
• Concerned about long-term cognitive safety (Spravato® is safer)
• Want an FDA-approved, REMS-certified treatment with robust regulatory oversight
• Can commit to in-office visits (cannot take home due to REMS)
• Live or work near a REMS-certified Spravato® provider (like KwikPsych Austin)

Choose IV Ketamine If You:

• Have severe, acute TRD where even rapid response within hours is critical
• Have access to an experienced ketamine clinic with good safety track record
• Willing/able to pay out-of-pocket ($3,000–18,000 for acute phase)
• Prefer IV administration or have needle phobia addressed
• Want flexibility in treatment location (IV ketamine more widely available than Spravato®)
• Limited insurance options and off-label use is not a concern
• Seeking higher efficacy expectations (though evidence is less robust)
• Planning short-term acute treatment only (6–12 months max) rather than long-term maintenance

Consider TMS Instead If You:

• Prefer non-medication approach to depression treatment
• Experience significant dissociation anxiety (TMS has zero dissociation)
• Have mild-to-moderate depression (TMS approved for these severity levels)
• Concerned about adverse effects in general (TMS side effects minimal)
• Have good insurance coverage (TMS widely covered; often $100–300/session copay)
• Living with psychotic depression (contraindicated for Spravato/ketamine)

Frequently Asked Questions

1. Which is actually more effective: Spravato® or IV ketamine?

This is the $64,000 question. The honest answer: We don't know for certain.

Spravato® evidence: Rigorous FDA-level randomized controlled trials showing 25–65% response rate in TRD.

IV ketamine evidence: Clinical reports, meta-analyses, and smaller studies suggesting 40–70% response, but less robust data.

Clinical reality: Anecdotally, some providers report ketamine produces faster/stronger initial response. Spravato® offers more standardized, regulated treatment. Choose based on access, insurance, and personal preference, not presumed efficacy difference.

2. Can I get IV ketamine at home?

Some ketamine clinics offer at-home infusions, but this is not standard and raises safety concerns (no medical monitoring during infusion, medication administration non-standardized). Most experts recommend office-based IV ketamine with standard monitoring protocols.

Spravato®, by REMS regulation, is never allowed at home—must always be office-based.

3. Does dissociation from Spravato® or ketamine cause permanent brain damage?

No. Dissociation during a 2-hour Spravato® session or IV ketamine infusion is a temporary, reversible state. By the end of monitoring, dissociation resolves. There is no evidence that acute dissociation causes structural brain damage or lasting cognitive problems.

Long-term concern: Chronic/repeated IV ketamine may carry cognitive risks with very high cumulative doses, but single-dose or short-term dissociation does not damage the brain.

4. Which treatment is safer long-term?

Spravato® is safer long-term based on available evidence:

• Esketamine maintains/improves cognition with chronic use
• Racemic IV ketamine's long-term safety is uncertain; may impair cognition with chronic dosing
• Spravato® has FDA oversight; IV ketamine does not

For short-term acute treatment (4–12 weeks), both are reasonably safe. For long-term maintenance (6+ months), Spravato® has better safety data.

5. Can I switch from IV ketamine to Spravato® or vice versa?

Yes, switching is possible, but:

• Some patients respond better to one than the other (individual variation)
• Switching requires washout period and re-evaluation
• Insurance/cost may change with switch
• Discuss with your psychiatrist; coordinate both providers if possible

6. What if I don't respond to Spravato® or IV ketamine?

Treatment failure happens in 35–75% of patients, depending on treatment chosen. Options:

• Optimize dosing/frequency of current treatment
• Combine with medication adjustments or psychotherapy
• Trial alternative rapid-acting treatment (switch Spravato® to ketamine or vice versa)
• Consider TMS, ECT, or other modalities
• Work with experienced psychiatrist to reassess and adjust plan

Disclaimer

This page is for informational purposes only and does not constitute medical advice. Both Spravato® and IV ketamine are prescription treatments with significant risks, benefits, and contraindications. Information presented is based on FDA-approved labeling, clinical trial data, and peer-reviewed literature as of March 2026.

Do not start, stop, or change either treatment without medical supervision. Only a qualified psychiatrist can determine which treatment is appropriate for your individual situation.

For diagnosis, treatment planning, and clinical decisions, schedule a consultation with Dr. Monika Thangada at KwikPsych Austin (737-367-1230) or a qualified ketamine clinic.

References & Clinical Evidence

1. Spravato® FDA Approval & Labeling

• U.S. Food and Drug Administration. (2019). Spravato® (esketamine) nasal spray: Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211243s000lbl.pdf

1. Spravato® Clinical Trials

• Canuso, C. M., et al. (2018). "Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide." American Journal of Psychiatry, 175(7), 620–630.
• Popova, V., et al. (2019). "Efficacy and Safety of Flexibly-Dosed Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression." American Journal of Psychiatry, 176(6), 428–438.

1. IV Ketamine for Depression

• Zarate, C. A., et al. (2006). "A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression." Archives of General Psychiatry, 63(8), 856–864.
• Newport, D. J., et al. (2015). "Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression." American Journal of Psychiatry, 172(10), 950–966.

1. Esketamine vs. Racemic Ketamine

• Singh, J. B., et al. (2016). "Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study." Biological Psychiatry, 80(6), 424–431.

1. Cognitive Safety

• Daly, E. J., et al. (2019). "Safety and Efficacy of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression." JAMA Psychiatry, 76(6), 582–592.
• Shiroma, P. R., et al. (2014). "Augmentation of Antidepressants with Ketamine in Treatment-Resistant Depression." ISRN Psychiatry, 2014, 623819.

1. Long-Term Safety Concerns with Ketamine

• Vollenweider, F. X., & Kometer, M. (2010). "The Neuropharmacology of Hallucinogens and Related Drugs." Biological Psychiatry, 68(3), 256–267.

1. REMS Regulatory Framework

• FDA. (2020). Risk Evaluation and Mitigation Strategy (REMS) Guidance Documents. https://www.fda.gov/drugs/drug-safety-and-availability/rems

Learn more: Spravato® Treatment  ·  Request an Appointment